


Please type a plus sign (+) inside this box → ☐

RPTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(Use for all correspondence after initial filing)

		Application Number	10/698,099
		Filing Date	October 31, 2003
		First Named Inventor	Schenk
		Group Art Unit	1648
		Examiner Name	Horning, M. S.
Total Number of Pages in This Submission	8	Attorney Docket Number	015270-008930US

ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form (orig. + 1 cc.) <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1) Return receipt postcard 2) Twenty-four (24) references
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430. Total number of pages <u>does not</u> include cited references.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Joe Liebeschuetz	Reg No. 37,505
Signature		
Date	January 30, 2007	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: January 31, 2007			
Typed or printed name	Christopher R. Fitting		
Signature		Date	January 31, 2007

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60971222



Effective on 12/08/2004
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4812)

FEE TRANSMITTAL

For FY 2005

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00)

Complete if Known

Application Number	10/698,099
Filing Date	October 31, 2003
First Named Inventor	Schenk
Examiner Name	Horning, M. S.
Art Unit	1648
Attorney Docket No.	015270-008930US

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number: 20-1430 Deposit Account Name: Townsend and Townsend and Crew LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Small Entity	Fee (\$)	Small Entity	Fee (\$)	Small Entity	Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Small Entity	
	Fee (\$)	Fee (\$)
Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent	50	25
Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent	200	100
Multiple dependent claims	360	180

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims	Fee (\$)	Fee Paid (\$)
-20 or HP =	x	\$	= \$0			
HP = highest number of total claims paid for, if greater than 20						
Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)			
-3 or HP =	x	\$	= \$0			
HP = highest number of independent claims paid for, if greater than 3						

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 =	/ 50 =	(round up to a whole number) x	=	

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other: Information Disclosure Statement (after office action)

Fees Paid (\$)

180.00

SUBMITTED BY

Signature		Registration No. (Attorney/Agent) 37,505	Telephone (650) 326-2400
Name (Print/Type)	Joe Liebeschuetz		Date January 30, 2007

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT
Attorney Docket No.: 015270-008930US
Client Reference No.: 334-US-NEW3

On _____

TOWNSEND and TOWNSEND and CREW LLP

By: _____



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk et al.

Application No.: 10/698,099

Filed: October 31, 2003

For: PREVENTION AND TREATMENT
OF SYNUCLEINOPATHIC DISEASE

Confirmation No.: 7805

Examiner: Michelle S. Horning

Art Unit: 1648

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

02/02/2007 AADOF01 00000002 201430 10698099
01 FC:1006 100.00 DA

Sir:


The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant

information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JOL:crf



PTO/SB/08A (07-06)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/698,099
Filing Date	October 31, 2003
First Named Inventor	Schenk, Dale B.
Art Unit	1648
Examiner Name	Michelle S. Horning
Attorney Docket Number	015270-008930US

Sheet	1	of	3
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-7,060,464	06-13-2006	Kim	
	AB	US-6,923,694	08-02-2005	Kim	
	AC	US-6,890,535	05-10-2005	Schenk	
	AD	US-6,866,850	03-15-2005	Schenk	
	AE	US-6,866,849	03-15-2005	Schenk	
	AF	US-6,858,704	02-22-2005	Kim	
	AG	US-6,787,144	09-07-2004	Schenk	
	AH	US-6,787,143	09-07-2004	Schenk	
	AI	US-6,787,140	09-07-2004	Schenk	
	AJ	US-6,787,139	09-07-2004	Schenk	
	AK	US-6,787,138	09-07-2004	Schenk	
	AL	US-6,761,888	07-13-2004	Schenk	
	AM	US-6,743,427	06-01-2004	Schenk	
	AN	US-6,504,080 B1	01-07-2003	Van Der Putten	
	AO	US-2005/0203010 A1	09-15-2005	Kim	
	AP	US-2005/0255113 A1	11-17-2005	Huston et al.	
	AQ	US-2003/0086938 A1	05-08-2003	Jensen et al.	
	AR	US-2002/0094335 A1	07-18-2002	Chalifour et al.	
	AS	US-2002/0187157 A1	12-12-2002	Jensen et al.	
	AT	US-2002/0151464 A1	10-17-2002	Wolozin et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AU	WO	05/013889	A2	02-17-2005			<input type="checkbox"/>
	AV	WO	04/009625	A2	01-29-2004			<input type="checkbox"/>
	AW	WO	01/053457	A2	07-26-2001			<input type="checkbox"/>
	AX	WO	99/40191	A1	08-12-1999			abst. only
	AY	WO	99/27944	A1	06-10-1999			<input type="checkbox"/>

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60959587

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
				Examiner Name	Michelle S. Horning
Sheet	2	of	3	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AZ	DE LUSTIG et al., "Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations," <u>Reviews in Neurosciences</u> , 5:213-225 (1994).	<input type="checkbox"/>	
	BA	FARRER, M. J., "Genetics of Parkinson disease: paradigm shifts and future prospects," <u>Nat. Rev. Genet.</u> , 7:306-318 (2006).	<input type="checkbox"/>	
	BB	GOLDSBY et al., "Vaccines," Chapter 18 from <i>Immunology, 4th Edition</i> , W.H. Freeman and Company, New York, pages 449-465 (2000).	<input type="checkbox"/>	
	BC	HANSEN et al., "Neurobiology of Disorders with Lewy Bodies," chapter 14, pages 173-182 from <i>Functional Neurobiology of Aging</i> , Hof et al., eds., Academic press (2001).	<input type="checkbox"/>	
	BD	HSIAO, K. K., "From prion diseases to Alzheimer's disease," <u>J. Neural. Transm. Suppl.</u> , 49:135-144 (1997).	<input type="checkbox"/>	
	BE	IRIZARRY et al., "nigral and Cortical Lewy Bodies and Dystrophic Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α -synuclein Immunoreactivity," <u>J. Neuropathology and Exp. Neurology</u> , 57(4):334-337 (1998).	<input type="checkbox"/>	
	BF	KOTZBAUER et al., "Lewy Body Pathology in Alzheimer's Disease," <u>J. Mol. Neuroscience</u> , 17(2):225-232 (2001).	<input type="checkbox"/>	
	BG	KUBY, J., pages 92-97 and 110 from <i>Immunology, Third Edition</i> , W.H. Freeman & Co., New York, (1997).	<input type="checkbox"/>	
	BH	LIPPA et al., "Antibodies to α -synuclein Detect Lewy Bodies in Many Down's Syndrome Brains with Alzheimer's Disease," <u>Ann. Neurology</u> , 45:353-357 (1999).	<input type="checkbox"/>	
	BI	LUCKING et al., "Review: Alpha-synuclein and parkinson's disease," <u>Cell Mol. Life Sci.</u> , 57:1894-1908 (2000).	<input type="checkbox"/>	
	BJ	MA et al., " α -Synuclein aggregation and neurodegenerative diseases," <u>J. Alzheimer's Disease</u> , 5:139-148 (2003).	<input type="checkbox"/>	
	BK	MASLIAH et al., "Effects of α -Synuclein Immunization in a Mouse Model of Parkinson's Disease," <u>Neuron</u> , 46:857-868 (2005).	<input type="checkbox"/>	
Examiner Signature			Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
				Examiner Name	Michelle S. Horning
Sheet	3	of	3	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BL	MUNCH et al., "Potential neurotoxic inflammatory responses to A β vaccination in humans," <u>J. Neural. Transm.</u> , 109:1081-1087 (2002).	<input type="checkbox"/>
	BM	PRIMAVERA et al., "Brain Accumulation of Amyloid- β in Non-Alzheimer Neurodegeneration," <u>J. Alzheimer's Disease</u> , 1:183-193 (1999).	<input type="checkbox"/>
	BN	VICKERS, J. C., "A Vaccine Against Alzheimer's Disease, Developments to Date," <u>Drugs Aging</u> , 19(7):487-494 (2002).	<input type="checkbox"/>
	BO	WAKABAYASHI et al., " α -Synuclein immunoreactivity in filial cytoplasmic inclusions in multiple system atrophy," <u>Neuroscience Letters</u> , 249:180-182 (1998).	<input type="checkbox"/>
	BP	WAKABAYASHI et al., "Widespread occurrence of α -synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies," <u>Neuropathology and Applied Neurobiology</u> , 25:363-368 (1999).	<input type="checkbox"/>
	BQ	WAKABAYASHI et al., "Accumulation of α -synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy," <u>Acta Neuropathol.</u> , 96:445-452 (1998).	<input type="checkbox"/>
	BR	Websters New World Dictionary, definition of "prophylactic", 3rd College edition, page 1078 (1988).	<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.